Skip to main content
Clinical Trials/NCT05910281
NCT05910281RecruitingNot Applicable

Rebound Pain and Related Factors in Patients Who Underwent Femoral Nerve Block for Postoperative Pain Control in Total Knee Arthroplasty

Gulhane Training and Research Hospital1 site in 1 country150 target enrollmentStarted: July 1, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
150
Locations
1
Primary Endpoint
Visual Analogue Scale

Study Overview

Brief Summary

The aim of this prospective observational study is to detect rebound pain and related factors in postoperative patients with total knee arthroplasty.

Detailed Description

Total knee arthroplasty is an effective treatment method for knee osteoarthritis and because it is an invasive method, more than 50% of patients experience postoperative pain. Peripheral nerve blocks are widely used for optimal pain control. The femoral block is a frequently preferred peripheral nerve block method for postoperative analgesia in total knee arthroplasty surgery. However, after peripheral nerve block, a condition called rebound pain (rebound pain), which is described as very severe pain, lasting about 2 hours, usually of the burning type, occurs. The aim of this prospective observational study is to detect rebound pain and related factors in postoperative patients with total knee arthroplasty.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • 18-80 years older age who underwent total knee arthroplasty

Exclusion Criteria

  • ASA score 4 or >4
  • Active infection
  • End stage organ failure
  • Pregnancy
  • Established diagnosis neuropsychiatric disease ( epilepsy, neuropathy, neuromuscular disease, cerebrovascular disease...)
  • Uses of oral corticosteroids

Outcomes

Primary Outcomes

Visual Analogue Scale

Time Frame: postoperative 3-5 days fellow-up

The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Gulhane Training and Research Hospital
Sponsor Class
Other Gov
Responsible Party
Principal Investigator
Principal Investigator

Bilal Katipoglu

M.D

Gulhane Training and Research Hospital

Study Sites (1)

Loading locations...

Similar Trials